Sex: M
Vaccine: VARZOS
Symptoms: Myocardial infarction, Pyrexia, Rash, Renal tubular necrosis, Respiratory failure
Clinical narrative: suffered spontaneous contractions / had a central line placed; tachycardic / (intubation removed after) and hypotensive; hypoxemia; Chronic bronquitis; never recovered pulmonary activity and died / Respiratory failure with hypoxemia; Elevated MI and shock; Elevated MI and shock; kidney problem / Diagnosed with membranous glomerulonephritis / worsened /hospitalized after getting worse; kidney problem / Diagnosed with membranous glomerulonephritis / worsened /hospitalized after getting worse; extremely ill kidneys shut down / developed acute renal failure; tubular necrosis; Metabolic encephalopathy (due to hyponatremia and anoxia); anoxia; Thrombocytopenia; hypotension (secondary to hypovolemia). /hypotensive; secondary to hypovolemia; Rash on the lower extremities; Decreased fluid and nourishment intake due to inability to eat and drink; Decreased fluid / due to inability to eat and drink; Hyponatremia; Transaminitis; Increased /creatinine; Increased BUN and creatinine; malaise; flu like symptoms / flu like illness; viral-like symptoms; myalgia; fever / Fever 103.9°F; multiorgan failure; rapidly decompensated with seizure; This case was reported by a physician via call center representative and described the occurrence of respiratory failure in a 62-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included biopsy (had a biopsy on February 2018.). Previously administered products included prednisone, ciclosporin, immunosuppressive therapy (had exacerbation of the problem and was treated with immunosuppressive therapy using rituximab twice) and rituximab. Concurrent medical conditions included renal disorder (had long standing kidney problems) and glomerulonephritis membranous (diagnosed with membranous glomerulonephritis). Concomitant products included rituximab.   On 22nd May 2018, the patient received the 1st dose of Shingrix. In May 2018, less than 2 weeks after receiving Shingrix, the patient experienced seizure (serious criteria hospitalization and GSK medically significant) and multi-organ failure (serious criteria hospitalization and GSK medically significant). On 22nd May 2018, the patient experienced influenza like illness (serious criteria hospitalization), viral infection (serious criteria hospitalization), myalgia (serious criteria hospitalization), fever (serious criteria hospitalization) and malaise (serious criteria hospitalization). On 26th May 2018, the patient experienced thrombocytopenia (serious criteria hospitalization and GSK medically significant), hypotension (serious criteria hospitalization), hypovolemia (serious criteria hospitalization), rash (serious criteria hospitalization), unable to eat (serious criteria hospitalization), fluid intake reduced (serious criteria hospitalization), hyponatremia (serious criteria hospitalization), transaminitis (serious criteria hospitalization), creatinine increased (serious criteria hospitalization) and blood urea nitrogen increased (serious criteria hospitalization). On 29th May 2018, the patient experienced respiratory failure (serious criteria death, hospitalization and GSK medically significant), myocardial infarction (serious criteria hospitalization and GSK medically significant), cardiogenic shock (serious criteria hospitalization and GSK medically significant), glomerulonephritis membranous (serious criteria hospitalization and GSK medically significant), condition aggravated (serious criteria hospitalization), acute renal failure (serious criteria hospitalization and GSK medically significant), tubular necrosis (serious criteria hospitalization and GSK medically significant), metabolic encephalopathy (serious criteria hospitalization and GSK medically significant), anoxia (serious criteria hospitalization and GSK medically significant), hypoxemia (serious criteria hospitalization and GSK medically significant) and chronic bronchitis (serious criteria hospitalization). On 30th May 2018, the patient experienced tachycardia (serious criteria hospitalization) and muscle contractions involuntary (serious criteria hospitalization). On 30th May 2018, the outcome of the respiratory failure was fatal. On an unknown date, the outcome of the myocardial infarction, cardiogenic shock, glomerulonephritis membranous, condition aggravated, acute renal failure, thrombocytopenia, tubular necrosis, metabolic encephalopathy, anoxia, seizure, hypoxemia, multi-organ failure, chronic bronchitis, hypotension, tachycardia, hypovolemia, muscle contractions involuntary, influenza like illness, viral infection, myalgia, fever, rash, malaise, unable to eat, fluid intake reduced, hyponatremia, transaminitis, creatinine increased and blood urea nitrogen increased were unknown. The patient died on 30th May 2018. The reported cause of death was respiratory failure. An autopsy was performed.   It was unknown if the reporter considered the respiratory failure, myocardial infarction, cardiogenic shock, glomerulonephritis membranous, condition aggravated, acute renal failure, thrombocytopenia, tubular necrosis, metabolic encephalopathy, anoxia, seizure, hypoxemia, multi-organ failure, chronic bronchitis, hypotension, tachycardia, hypovolemia, muscle contractions involuntary, influenza like illness, viral infection, myalgia, fever, rash, malaise, unable to eat, fluid intake reduced, hyponatremia, transaminitis, creatinine increased and blood urea nitrogen increased to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient had long standing kidney problems and was various drugs for the past 20 years. The patient had last Rituximab treatment on 16th May 2018. As per MD (Doctor of Medicine) insistence patient got Shingrix vaccine. The patient experienced flu like symptoms, myalgia, fever and malaise and his condition worsened. On 26th May 2018, the patient was hospitalized after getting worse. The patient got extremely ill, kidneys shut down, there was hypotension (secondary to hypovolemia), decreased fluid and nourishment intake due to inability to eat and drink, fever 103.9 degree Fahrenheit, rash on the lower extremities, thrombocytopenia, hyponatremia decreased sodium, blood urea nitrogen increased and creatinine increased and transaminitis. Initial hospital could not do dialysis due to lack of equipment and was transferred to reporters hospital with a diagnose of membranous glomerulonephritis. On 29th May 2018, the patient was transferred to reporter's hospital and patient died in less than 24 hours. The patient developed acute renal failure with tubular necrosis, respiratory failure with hypoxemia, chronic bronchitis (found in reporter's hospital), metabolic encephalopathy (due to hyponatremia and anoxia), elevated MI (myocardial infarction) and shock. The patient had viral-like symptoms, tests for several common viruses came negative. As per physician notes patient rapidly decompensated with seizure and multiorgan failure, questionable meningitis versus immune response; pathologist (reporter) confirms patient did not have meningitis. On 30th May 2018, the patient was declared DNR (do-not-resuscitate) by family and later became asystolic, suffered spontaneous contractions and had a central line placed. The patient became tachycardic and hypotensive and was removed from intubation and 2 minutes later never recovered pulmonary activity and died. The health care professional was performing autopsy on a patient. No vaccine administration information available to reporter. The reporter consented to follow-up. This case had been linked with US2021090816, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021090816:same reporter (wife´s case); Reported Cause(s) of Death: Respiratory failure